Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Is Biogen a Smart Biotech Stock to Buy Right Now?
09:13am, Thursday, 29'th Sep 2022 The Motley Fool
New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past.
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
09:09am, Thursday, 29'th Sep 2022 Benzinga
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The tria
Netflix, Biogen And Other Big Gainers From Wednesday
07:45am, Thursday, 29'th Sep 2022 Benzinga
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.
Acumen Pharmaceuticals, Inc. (NAS
Is Biogen a Smart Biotech Stock to Buy Right Now?
05:13am, Thursday, 29'th Sep 2022
New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past.
Why Moderna Stock Lagged the Market Today
09:28pm, Wednesday, 28'th Sep 2022 The Motley Fool
The company's latest regulatory advance is overshadowed by developments with another biotech.
Biogen stock pumps 48% amid upgrade. What to watch out for
09:25pm, Wednesday, 28'th Sep 2022 Invezz
Biogen Inc. (NASDAQ:BIIB) gained more than 48% on Wednesday’s stock premarket. The stock was among the top trends on popular social trading platforms. There were definite reasons. On Tuesday, compan
Biogen and Eisai report successful test on Alzheimer's treatment
08:00pm, Wednesday, 28'th Sep 2022
CNBC's Shep Smith reports on positive news regarding a drug trial from Biogen and Japan's Eisai, which showed a 27% decrease in cognitive decline among early stage Alzheimer's patients.
Dow rebounds over 500 points in final hour of trade as Treasury and UK government bond yields fall after BOE intervention
07:09pm, Wednesday, 28'th Sep 2022 MarketWatch
U.S. stock indexes on Wednesday turned higher, helped by a fall in Treasury yields and a surprise intervention from the Bank of England in the U.K. gilt market, but Wall Street stocks were still in da
Alphabet To $136? Plus This Analyst Slashes PT On United Natural Foods
07:01pm, Wednesday, 28'th Sep 2022 Benzinga
Truist Securities cut the price target on Alphabet Inc. (NASDAQ: GOOGL) from $145 to $136. Truist Securities analyst Youssef Squali maintained a Buy rating on the stock. Alphabet shares rose 2.5% to
Big win for Biogen: Alzheimer's drug results spark huge gains
06:26pm, Wednesday, 28'th Sep 2022
Oppenheimer's Jared Holz on Biogen after the company's stock soared on positive Alzheimer trials. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Karen Finerman and Courtney
Biogen Alzheimer's drug may be 'first effort of a clear win': Analyst
06:21pm, Wednesday, 28'th Sep 2022
Baird Senior Research Analyst Brian Skorney joins Yahoo Finance Live to discuss the breakthrough of Biogen's Alzheimer's drug, which is pushing the stock higher.
Biogen Stock Erupts After Alzheimer’s Drug Hits Jackpot
06:07pm, Wednesday, 28'th Sep 2022 Investing.comBiogen stock pumps 48% amid upgrade. What to watch out for
05:25pm, Wednesday, 28'th Sep 2022
Biogen Inc. (NASDAQ:BIIB) gained more than 48% on Wednesday's stock premarket. The stock was among the top trends on popular social trading platforms.
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
04:40pm, Wednesday, 28'th Sep 2022 Benzinga
Gainers
Prothena Corporation plc (NASDAQ: PRTA) shares climbed 76.4% to $54.54 after Biogen and Eisai Co. Ltd. announced late Tuesday positive results from a late-stage study of their Alzheimer’s
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
04:30pm, Wednesday, 28'th Sep 2022 Benzinga
Biogen Inc (NASDAQ: BIIB) and its partner Eisai Limited (OTC: ESALY) announced a significant surprise, with lecanemab's confirmatory Phase 3 Clarity study meeting the primary endpoint in early Alz
